mmae

Utilizing the highly specific targeting mechanism of a monoclonal antibody, ADCs selectively deliver extremely powerful cytotoxic agents to tumor cells that express the particular cell surface membrane receptor. Made into an ADC, the drug efficacy of auristatins has been dramatically increased, along with an expanded therapeutic window. One example for a well-studied ADC containing auristatin as payload is Brentuximab vedotin. Brentuximab vedotin is an ADC composed of an auristatin analog, monomethylauristatin-E (MMAE) conjugated to an anti-CD30 Ab through a protease cleavable linker. This ADC has been shown to cause continuous positive responses in suppressing tumor regression in majority of patients with relapsed or refractory CD30+ lymphomas. https://www.creative-biolabs.com/adc/auristatins.htm